Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ICR and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality Screens
The ICR and Horizon Discovery (Horizon) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.
New Test Could Reveal Chemotherapy Benefit in 24 Hours
Scientists have developed a new test to indicate whether the most commonly-used chemotherapy drug will benefit a breast cancer patient within 24 hours of taking it. The test also identifies patients who may benefit from PARP inhibitors, a promising new class of cancer treatment.
Herpes Virus Treats Head and Neck Cancer Patients
A genetically engineered cold sore virus has been used to treat head and neck cancer patients in a Phase I/II clinical trial.
ICR Chief Executive to Become Deputy Chairman of the Wellcome Trust
He will take up the position at the independent, global biomedical charity in October.
Therapy Reduces Dangerous Side-effects
Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect.
Breast Cancer Drugs May Treat Prostate Cancer
The way prostate cancer develops in men who have an altered ‘breast cancer gene’ is the same route by which breast cancer develops in women with the same mutation.
Cancer Centres Launch Academic Partnership
A new academic partnership will be officially launched next week when Mount Vernon Cancer Centre joins the long-standing collaboration between The Royal Marsden and The Institute of Cancer Research (ICR).
Three New Testicular Cancer Risk Variants
A study led by The Institute of Cancer Research (ICR) has identified three new genetic risk factors for testicular cancer.
Mutation Confirmed as Melanoma Drug Target
A mutation present in around half of malignant melanomas has been confirmed as a strong drug target, according to research published today in Science Translation Medicine.
Testicular Cancer Chemo Risk Examined
Long-term side-effects including nerve pain, hearing loss and discoloured fingers and toes are a risk for men given chemotherapy treatment for testicular cancer, new research shows.
Cancer Drug Researcher Receives Royal Society of Chemistry Award
Professor Paul Workman from The Institute of Cancer Research (ICR) has received a prestigious award from the Royal Society of Chemistry for his work in discovering exciting new anti-cancer drugs.
Genetic Mutation Shown to Trigger Melanoma
Researchers have discovered that a genetic mutation found in some malignant melanomas can initiate development of this most deadly form of skin cancer, according to a study published today in the journal Cancer Research.